NCT05911230 Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
| NCT ID | NCT05911230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Glioblastoma (GBM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2022-11-24 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2022-11-24 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.
Eligibility Criteria
Inclusion Criteria: * Patients with histopathologically proven glioblastoma or brain metastasis and suspected tumor progress on standard MRI after first line therapy and who are candidates for elective surgical resection. * Able to give informed consent Exclusion Criteria: * Contraindications to MRI (e.g. claustrophobia, pacemaker or other implants without MRI-approval, pregnancy) * Patients in a life-threatening condition * Patients in need of emergent surgery * Histopathological analyses of insufficient quality * Unable to give informed consent * Age \<18 Years
Contact & Investigator
Dominik Cordier, PD Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT05911230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioblastoma (GBM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05911230 currently recruiting?
Yes, NCT05911230 is actively recruiting participants. Contact the research team at dominik.cordier@usb.ch for enrollment information.
Where is the NCT05911230 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT05911230 clinical trial?
NCT05911230 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Dominik Cordier, PD Dr. med. at University Hospital, Basel, Switzerland. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.